Coronavirus Vaccine Reaches The Final Stage of Clinical Trials

Coronavirus Vaccine Reaches The Final Stage of Clinical Trials

The first healthy volunteer has now received a candidate coronavirus vaccine developed by Imperial researchers. This was announced by BTA. The vaccine has been developed with pharmaceuticals group AstraZeneca known as ChAdOx1 nCoV-19.

He also engaged with numerous others part of the trial including some of the 4,000 volunteers now enrolled for the vaccine's testing procedures.

"As we enter winter in South Africa and pressure increases on public hospitals, now more than ever we need a vaccine to prevent infection by COVID-19", University of Witwatersrand (Wits) vaccinology professor Shabir Madhi said.

He met Prof Sarah Gilbert, who is leading the trial, and Prof Andrew Pollard, the group's director. Several others are expected to receive a first dose over the coming days. In which many countries now also see success.

"This vaccine has shown very good results in trials with chimpanzees and has already moved on to the next phase of human trials".

All African countries now have coronavirus lab testing capacity - World Health Organization chief
Indeed, the vast majority of vaccines in early development fail, ' the World Health Organization noted in a document about COVAX. Currently, there are at least four vaccines in clinical trials in the US, UK and Australia.

He added: "We now eagerly await rapid recruitment to the trial so that we can assess both the safety of the vaccine and its ability to produce neutralising antibodies which would indicate an effective response against Covid-19". The University of Witwatersrand is collaborating with the University of Oxford and the Oxford Jenner Institute on the South African trial.

Imperial's RNA vaccine uses synthetic strands of genetic code based on the genetic material of Sars-CoV-2, the coronavirus responsible for the pandemic. World Health Organization is drafting guidelines for the ethical distribution of COVID-19 vaccines.

"We are now poised to test the vaccine in the dose evaluation phase before moving forward to evaluating it in larger numbers", said Dr Katrina Pollock, the lead investigator in the trial.

"And understanding that it's not likely that things will get back to normal until there is a vaccine, so wanting to be part of that progress as well".

There has been much debate internationally, including at the World Health Organisation, that the vaccine, when it is found, be made available to all countries at low or even no cost to developing countries, and not only be sold in rich and developed nations only.

Related Articles